Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
// Neel M. Fofaria 1 , Dennie T. Frederick 2, 3 , Ryan J. Sullivan 2, 3 , Keith T. Flaherty 2, 3 , Sanjay K. Srivastava 1 1 Department of Biomedical Sciences and Cancer Biology Center, Texas Tech University Health Sciences Center, Amarillo, TX, USA 2 Harvard Medical School, Boston, Massachusetts, USA 3 Division of Medical Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA Correspondence to: Sanjay K. Srivastava, e-mail: sanjay.srivastava@ttuhsc.edu Keywords: BRAF inhibitors, de novo and acquired resistance, MEK1/2 inhibitors, Mcl-1, combination therapy Received: August 21, 2015 Accepted: September 20, 2015 Published: October 14, 2015 ABSTRACT Melanoma harboring BRAF mutations frequently develop resistance to BRAF inhibitors, limiting the impact of treatment. Here, we establish a mechanism of resistance and subsequently identified a suitable drug combination to overcome the resistance. Single treatment of BRAF mutant melanoma cell lines with vemurafenib or dabrafenib (BRAF inhibitors) alone or in combination with trametinib (MEK1/2 inhibitor) resulted in overexpression of Mcl-1. Overexpression of Mcl-1 in A375 and SK-MEL-28 by transfection completely blocked BRAF and MEK1/2 inhibitor-mediated inhibition of cell survival and apoptosis. Melanoma cells resistant to BRAF inhibitors showed massive expression of Mcl-1 as compared to respective sensitive cell lines. Silencing of Mcl-1 using siRNA completely sensitized resistant melanoma cells to growth suppression and induction of apoptosis by BRAF inhibitors. In vivo , vemurafenib resistant A375 xenografts implanted in athymic nude mice showed substantial tumor growth inhibition when treated with a combination of vemurafenib and Mcl-1 inhibitor or siRNA. Immunohistochemistry and western blot analyses demonstrated enhanced expression of Mcl-1 and activation of ERK1/2 in vemurafenib-resistant tumors whereas level of Mcl-1 or p-ERK1/2 was diminished in the tumors of mice treated with either of the combination. Biopsied tumors from the patients treated with or resistant to BRAF inhibitors revealed overexpression of Mcl-1. These results suggest that the combination of BRAF inhibitors with Mcl-1 inhibitor may have therapeutic advantage to melanoma patients with acquired resistance to BRAF inhibitors alone or in combination with MEK1/2 inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wagle, N., Van Allen, E. M., Treacy, D. J., Frederick, D. T., Cooper, Z. A., Taylor-Weiner, A., Rosenberg, M., Goetz, E. M., Sullivan, R. J., Farlow, D. N., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0631 · Cited by 478 · cited 1×
“Therefore, a combination of BRAF inhibitor (dabrafenib) and MEK1/2 inhibitor (trametinib) was approved in early 2014 for the treatment of metastatic melanoma, to which incidences of resistance has already been observed [12, 13].”
Self-citationDomina, A. M., Vrana, J. A., Gregory, M. A., Hann, S. R., & Craig, R. W. (2004) · Oncogene · doi:10.1038/sj.onc.1207692 · Cited by 327
Verhaegen, M., Bauer, J. A., Martín de la Vega, C., Wang, G., Wolter, K. G., Brenner, J. C., Nikolovska-Coleska, Z., Bengtson, A., Nair, R., Elder, J. T., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1748 · Cited by 140 · cited 1×
“TW-37 binds to Bcl-XL with a 5 fold lower affinity (Ki≈1200 nM) [35, 36].”
Faber, A. C., Coffee, E. M., Costa, C., Dastur, A., Ebi, H., Hata, A. N., Yeo, A. T., Edelman, E. J., Song, Y., Tam, A. T., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0315 · Cited by 124 · cited 1×
“Hence, Mcl-1 has been identified as an important target in majority of human cancers [19, 20] and several therapeutic strategies focusing on Mcl-1 inhibition are currently under development [21–25].”
Cited by
Luebker, S. A., & Koepsell, S. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00268 · Cited by 194
BRAF — a tumour-agnostic drug target with lineage-specific dependencies
Hanrahan, A. J., Chen, Z., Rosen, N., & Solit, D. B. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00852-0 · Cited by 136
Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies
Montero, J., Gstalder, C., Kim, D. J., Sadowicz, D., Miles, W., Manos, M., Cidado, J. R., Paul Secrist, J., Tron, A. E., Flaherty, K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12477-y · Cited by 80
Self-citationKoumaki, K., Kontogianni, G., Kosmidou, V., Pahitsa, F., Kritsi, E., Zervou, M., Chatziioannou, A., Souliotis, V. L., Papadodima, O., & Pintzas, A. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.166061 · Cited by 36
Metadata
- Authors
- Fofaria, N. M., Frederick, D. T., Sullivan, R. J., Flaherty, K. T., & Srivastava, S. K.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-10-14
- Volume
- 6
- Issue
- 38
- Pages
- 40535-40556
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1868879889
- Cited by
- 62
- References
- 4
- FWCI
- 2.32
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma. https://app.cochat.ai/papers/10.18632/oncotarget.5755
- The paper
- Fofaria, N. M., Frederick, D. T., Sullivan, R. J., Flaherty, K. T., & Srivastava, S. K. (2015). Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma. Oncotarget. https://doi.org/10.18632/oncotarget.5755
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.